Contineum Therapeutics Inc

For the period ended Mar 31, 2024. Filed May 16, 2024.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2024 · Filed May 16, 2024

CTNM$10.56+2.5%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Condensed Statements of Convertible Preferred Stock and Stockholders’ Deficit

(in thousands, except share data)

Additional · Accumulated Other · Total
Convertible Preferred Stock · Common Stock · Paid-in · Comprehensive · Accumulated · Stockholders'
	Shares	Amount	Shares	Amount	Capital	Income (Loss)	Deficit	Deficit
Balance at December 31, 2023	15,906,236	$192,620	2,349,554	$2	$7,098	$108	$(75,144)	$(67,936)
Exercise of stock options	—	—	34,872	—	122	—	—	122
Stock-based compensation expense	—	—	—	—	768	—	—	768
Net loss	—	—	—	—	—	—	(8,417)	(8,417)
Unrealized loss on marketable securities	—	—	—	—	—	(166)	—	(166)
Balance at March 31, 2024	15,906,236	$192,620	2,384,426	$2	$7,988	$(58)	$(83,561)	$(75,629)

Additional · Accumulated Other · Total
Convertible Preferred Stock · Common Stock · Paid-in · Comprehensive · Accumulated · Stockholders'
	Shares	Amount	Shares	Amount	Capital	Income (Loss)	Deficit	Deficit
Balance at December 31, 2022	11,889,674	$132,482	2,259,734	$2	$4,726	$(76)	$(97,864)	$(93,212)
Vesting of shares of common stock subject to repurchase	—	—	5,245	—	5	—	—	5
Exercise of stock options	—	—	7,146	—	8	—	—	8
Stock-based compensation expense	—	—	—	—	494	—	—	494
Net loss	—	—	—	—	—	—	(4,824)	(4,824)
Unrealized gain on marketable securities	—	—	—	—	—	67	—	67
Balance at March 31, 2023	11,889,674	$132,482	2,272,126	$2	$5,233	$(9)	$(102,688)	$(97,462)

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.